Reyna et al. develop BTSA1, a pharmacologically optimized BAX activator, which leads to sustained BAX-mediated apoptosis in leukemia cell lines and in AML xenografts, providing a novel therapeutic strategy in AML [88]. This evidence concerns the gene BAX and acute myeloid leukemia.